• Competitive ELISA for detection of neutralising antibodies
  • Independent of antibody isotype
  • Low sample volume
  • Hightly sensitive and specific (in house evaluation)
  • Ready to use reagents

PRO-C3 is a marker with high accuracy to detect NASH, advanced alcohol-related liver fibrosis, and many liver related and other major diseases. The diagnostic accuracy of PRO-C3 can be further improved by using the ADAPT algorithm in which the test outperforms currently available non-patented serological fibrosis markers.

To assess the diagnostic accuracy of PRO-C3, the ADAPT score and best-performing non-patented serological test to detect advanced alcohol-related liver fibrosis. The accuracy of PRO-C3 was good with an AUROC of 0.85 (95% CI 0.79-0.90). The best-performing non-patented test was the Forns index with an AUROC of 0.83 (95% CI 0.78-0.89). The ADAPT algorithm performed better as compared to both the Forns index and PRO-C3 alone with an

Serological biomarkers reflecting the formation of type III collagen (PRO-C3) and degradation of type I (C1M) and III collagen (C3M) were evaluated in a real-world cohort of 178 newly diagnosed IPF patients. Blood samples and clinical data were collected at baseline, six, and 12 months. Baseline and longitudinal biomarker levels were related to disease progression of IPF (defined as ≥ 5% decline in forced vital capacity (FVC) and/or ≥ 10% decline in diffusing capacity for carbon monoxide (DLco) and/or all-cause mortality at 12 months). Furthermore, we analysed differences in percentage change of biomarker levels from baseline between patients receiving antifibrotic treatment or not. Baseline levels of type I and III collagen turnover were associated with disease progression within 12 months in a real-world cohort of IPF patients. Longitudinal biomarker levels of type I and III collagen turnover were related to progressive disease. Moreover, antifibrotic therapy did not affect type I and III collagen turnover biomarkers in these patients. PRO-C3 and C1M may be potential biomarkers for a progressive disease behavior in IPF.

Therapeutic area
Gastroenterology, Cardiovascular diseases, Cancer, Hepatic diseases, Respiratory diseases, Renal diseases, Dermatology, Rheumatology, Metabolic dysregulation

Biomarker panels
Lung Fibrosis, HepNIT Panel™: Hepatic Non-invasive Tests, Bridging Fibrosis, Liver Fibrosis Outcome, Tissue Fibrosis, Fibrosis / Fibroblasts, Kidney Disease Activity, Kidney Outcome, Kidney Preclinical, Heart Fibrosis, Heart Outcome, Tissue Fibrosis, Mucosal Damage Resolution, Systemic Sclerosis

Fibrogenesis, ECM formation

Alternative names

Please don't hesitate to contact us if you have any questions or other inquiries.

Are you interested in learning more about Nordic Bioscience?
Enter your information in the form and a representative will contact you shortly.

By submitting this form you agree to our terms and conditions.